BACKGROUND: The impact of chronic hepatitis B virus (HBV) infection on viral suppression, immune recovery and mortality in HIV-1 infected patients on highly active antiretroviral treatment (HAART) is a matter of debate. The impact of HBeAg status is unknown. METHODS: This prospective cohort study included all adult Danish HIV-1 infected patients who started HAART between 1 January 1995 and 1 December 2006 (3180 patients). Patients were classified as chronic HBV-infected (6%), HBV-negative (87%) or HBV-unknown (7%). HBV-positive patients were divided into HBeAg-positive or -negative (3.0 vs. 2.6%). Study endpoints were viral load, CD4 cell count and mortality. RESULTS: HBV co-infection had no impact on response to HAART regarding viral suppression or immune recovery. HBV co-infection was associated with several outcomes: overall mortality [mortality rate ratio (MRR) 1.5; 95% confidence interval (CI) 1.1-2.1], liver-related mortality (MRR 4.0; 95% CI 1.6-9.9) and AIDS-related deaths (MRR 1.7; 95% CI 1.0-3.0). The presence of HBeAg did not influence patients' response to HAART. CONCLUSIONS: In HIV patients, chronic HBV infection has no impact on response to HAART concerning viral load and increase in CD4 cell count. However, co-infected patients have an increased mortality compared to HIV-monoinfected patients.
BACKGROUND: The impact of chronic hepatitis B virus (HBV) infection on viral suppression, immune recovery and mortality in HIV-1 infectedpatients on highly active antiretroviral treatment (HAART) is a matter of debate. The impact of HBeAg status is unknown. METHODS: This prospective cohort study included all adult Danish HIV-1 infectedpatients who started HAART between 1 January 1995 and 1 December 2006 (3180 patients). Patients were classified as chronic HBV-infected (6%), HBV-negative (87%) or HBV-unknown (7%). HBV-positive patients were divided into HBeAg-positive or -negative (3.0 vs. 2.6%). Study endpoints were viral load, CD4 cell count and mortality. RESULTS:HBV co-infection had no impact on response to HAART regarding viral suppression or immune recovery. HBV co-infection was associated with several outcomes: overall mortality [mortality rate ratio (MRR) 1.5; 95% confidence interval (CI) 1.1-2.1], liver-related mortality (MRR 4.0; 95% CI 1.6-9.9) and AIDS-related deaths (MRR 1.7; 95% CI 1.0-3.0). The presence of HBeAg did not influence patients' response to HAART. CONCLUSIONS: In HIVpatients, chronic HBV infection has no impact on response to HAART concerning viral load and increase in CD4 cell count. However, co-infectedpatients have an increased mortality compared to HIV-monoinfectedpatients.
Authors: H N Kim; J Scott; A Cent; L Cook; R A Morrow; B Richardson; K Tapia; K R Jerome; G Lule; G John-Stewart; M H Chung Journal: J Viral Hepat Date: 2011-05-13 Impact factor: 3.728
Authors: Jules B Tchatchueng Mbougua; Christian Laurent; Charles Kouanfack; Anke Bourgeois; Laura Ciaffi; Alexandra Calmy; Henri Gwet; Sinata Koulla-Shiro; Jacques Ducos; Eitel Mpoudi-Ngolé; Nicolas Molinari; Eric Delaporte Journal: BMC Public Health Date: 2010-03-01 Impact factor: 3.295
Authors: Helen M Chun; Octavio Mesner; Chloe L Thio; Ionut Bebu; Grace Macalino; Brian K Agan; William P Bradley; Jennifer Malia; Sheila A Peel; Linda L Jagodzinski; Amy C Weintrob; Anuradha Ganesan; Mary Bavaro; Jason D Maguire; Michael L Landrum Journal: J Acquir Immune Defic Syndr Date: 2014-06-01 Impact factor: 3.731
Authors: Christopher J Hoffmann; Eric C Seaberg; Stephen Young; Mallory D Witt; Kristin D'Acunto; John Phair; Chloe L Thio Journal: AIDS Date: 2009-09-10 Impact factor: 4.177
Authors: John Rusine; Pascale Ondoa; Brenda Asiimwe-Kateera; Kimberly R Boer; Jean Marie Uwimana; Odette Mukabayire; Hans Zaaijer; Julie Mugabekazi; Peter Reiss; Janneke H van de Wijgert Journal: PLoS One Date: 2013-05-22 Impact factor: 3.240